Actavis Launches U.S. Generic Specialty Injectable Portfolio
Actavis will immediately begin marketing approximately 20 injectable products across a number of therapeutic categories in the U.S. The Company will be... Read More
+91 789 2456 581 | info@nckpharma.com
Sign In
|Sign Up
Please sign in first
Not a member?
Please simply create an account before buying/booking any courses.
Create an account for free!
- Home
- NCK services
- Course List
- Admission
- Course Quick Glance
- Features of Online Courses
- Course Catalogue
- Course Application form
- Admission Notification & Special Offers
- Frequently asked question related to KPE courses
- Prospect Identification Process
- Final Examination Registration
- How to change / reset password?
- Course Upgrade
- Verify Course Certificate
- Request for Course Completion Certificate
- Corporate Training
- Knowledge Base
Tag
generic speciality injectables
Our Popular Courses
Recent Articles
- Insight on Alteogen’s non-exclusive licensing deal for ALT-B4 to a top 10 global pharma
- Pharma Strategic Deal: Astellas Pharma to acquire Audentes Therapeutics for about $3 billion
- Pharma Business Development – Competency Test. Check your competency
- Case study: Novartis to acquire The Medicines Company for $9.7 billion, get hold of inclisiran, a cholesterol drug
- What is USFDA Purple Book? What it’s significance?
- USFDA approved Pfizer’s Abrilada, a biosimilar of Humira
- Pfizer’s Upjohn and Mylan merged business entity will be namea as Viatris
- Bayer and Dewpoint Therapeutics co-development deal for cardiovascular and gynecological diseases
- Sandoz to Acquire Japanese Biz of AGI
- Selumetinib NDA Submission for Neurofibromatosis Type 1 (NF1) granted Priority Review
- Insignt on Roche’s Up-to-$1.4Billion Promedior Acquisition
- Case Study: 505(b)(2) filing pathway – USFDA approval of Vumerity
- What is the significance of Clinical Hold of investigational molecules?
- US FDA places partial hold on Novartis’ AVXS-101 intrathecal study
- Zentiva to acquire CEE pharma business of Alvogen
- Insighht on USFDA approval of Trikafta
- How much is the average ideal royalty rate in pharmaceutical and biopharmaceutical business deal?
- Pharma Licensing: Explore differences between Royalty rate & Royalty base
- Takeda Divesting Select OTC and Non-core Assets of takeda to Acino
- GSK to disinvest Rabipur and Encepur – vaccine for USD 1.1 billion